Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress

- Oral and Poster Presentations to Highlight Preclinical Research for ARCUS® Gene Editing

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre.

Oral Presentation:

Title: Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate Hepatitis B virus in vivo
Date and Time: Wednesday, October 12, 2022, 8:30 AM - 10:40 AM BST
Session Title: Parallel 2a, Vaccine technologies & infectious diseases
Location & Poster Number: Pentland and Sidlaw, OR14
Presenter: Derek Jantz, Ph.D., Chief Scientific Officer & Strategy

Poster Presentations:

Title: ARCUS gene editing of Apolipoprotein C3 results in substantial reduction in serum triglycerides in vivo
Date and Time: Wednesday, October 12, 2022, 7:30 PM - 9:00 PM BST
Session Title: Gene and epigenetic editing
Location & Poster Number: Cromdale Hall, Level 2, Poster# P441
Presenter: Wendy Shoop, Scientist

Title: Specific elimination of m.3243A>G mutant mitochondrial DNA using mitoARCUS in cultured cells and a novel xenograft mouse model
Date and Time: Thursday, October 13, 2022, 5:30 PM - 7:15 PM BST
Session Title: Gene and epigenetic editing
Location & Poster Number: Cromdale Hall, Level 2, Poster #P422
Presenter: Wendy Shoop, Scientist

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005408/en/

Investor Contact:

Mei Burris

Director, Investor Relations and Finance

Mei.Burris@precisionbiosciences.com

Media Contact:

Maurissa Messier

Senior Director, Corporate Communications

Maurissa.Messier@precisionbiosciences.com

Source: Precision BioSciences, Inc.